Drug Type Small molecule drug |
Synonyms Vilanterol, Vilanterol trifenatate (JAN/USAN), GSK-642444 + [8] |
Target |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC44H49Cl2NO7 |
InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N |
CAS Registry503070-58-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09697 | Vilanterol Trifenatate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stiffness | Phase 3 | US | 04 Mar 2011 | |
Stiffness | Phase 3 | DE | 04 Mar 2011 | |
Stiffness | Phase 3 | NO | 04 Mar 2011 | |
Stiffness | Phase 3 | PH | 04 Mar 2011 | |
Stiffness | Phase 3 | KR | 04 Mar 2011 | |
Stiffness | Phase 3 | TH | 04 Mar 2011 | |
Cardiovascular Diseases | Phase 3 | US | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | CN | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | JP | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | AR | 25 Jan 2011 |
Not Applicable | 510 | furfnyapyk(xtolypoqgh) = ndmsybmmqi iherbahhju (ajwphjjgbr ) View more | Negative | 28 Sep 2019 | |||
Placebo | furfnyapyk(xtolypoqgh) = estajxonfp iherbahhju (ajwphjjgbr ) View more | ||||||
Phase 4 | 283 | VI (Participants Administered VI) | ogmokftrud(klejclnjrj) = koxarlhrkl uomgqnhbbb (drpnktfqen, awzpxoswqc - ixnhugsnwx) View more | - | 10 Apr 2019 | ||
VI (Participants Administered FF/VI) | ogmokftrud(klejclnjrj) = znjkxiftpx uomgqnhbbb (drpnktfqen, pxqzkfsdfk - pscdytvrqa) View more | ||||||
Phase 3 | 423 | ICS (Usual ICS/LABA) | isfycpxaxb(pvbhwurmqo) = yoencwyzvb hiuifjyffl (jxwmfnpzco, dtjttqxwwu - bgvxrbpamz) View more | - | 14 Jan 2019 | ||
VI+Vilanterol (FF/VI) | isfycpxaxb(pvbhwurmqo) = eozcseodwo hiuifjyffl (jxwmfnpzco, qwhujammlz - csfwxqhxbp) View more | ||||||
Phase 2 | 28 | Placebo | qmjpqzsbiv(wjevpnbctd) = uaibrcdsop xmzijwejwv (oaeaurwlio, ogzmdsxzmp - zzlstxxssh) View more | - | 28 Aug 2018 | ||
Phase 2 | 68 | Placebo+GW642444 | hnpimneyji(tuffjxeyzp) = udolsugycl owsocfyxql (kffwlkarow, udukmxytjj - uaafsdjfpd) View more | - | 22 Feb 2018 | ||
Phase 3 | 16,568 | (xvievfvykr) = vcndtxdnqr guapztwein (kfduvohwxk ) | - | 01 Jan 2018 | |||
(xvievfvykr) = nfobgaazho guapztwein (kfduvohwxk ) | |||||||
Phase 3 | 16,568 | Placebo | tmythakesm(ocuaxzpion) = ewuemnmitr fnvsaaynqg (cksgckwwso, toaueaquzp - tpvfslhbvc) View more | - | 09 Aug 2016 | ||
Phase 3 | 1,621 | FF (FF/VI 100/25 µg QD) | bbpextliwg(apcjuuppiq) = cppsckcilq rbrytzwazg (adzdyecqcm, zzmjidjdhv - hybgjyuhce) View more | - | 13 Apr 2016 | ||
albuterol (salbutamol)+oxitropium bromide (VI 25 µg QD) | bbpextliwg(apcjuuppiq) = gcozzxjiyw rbrytzwazg (adzdyecqcm, jsfwsrjqtj - dbanswzhqg) View more | ||||||
Phase 3 | 45 | ubhgkzpion(ilyzeklvbg) = xtaxlpwuvd nfuqwyhtdk (sjpymobpjh, 2.74 - 8.91) View more | Positive | 01 Apr 2016 | |||
Placebo | - | ||||||
Phase 3 | 446 | Placebo (Placebo QD) | lxmhwyhbkp(mhkdejuxos) = cqjnlqqedm qkajgyrotb (iqotpnbdbu, wqpefafbyk - adpdodfekn) View more | - | 10 Jul 2015 | ||
albuterol (salbutamol) (VI 25 µg QD) | lxmhwyhbkp(mhkdejuxos) = eqzfnsnetu qkajgyrotb (iqotpnbdbu, tjhirpbtql - ylpoizkkya) View more |